Correlation of her 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma

Abstract

The purpose of this study was to determine relationship between HER-2/neu status and estrogen receptor, progesterone receptor, grade and age by comparing fluorescence in situ hybridization and immunohistochemistry. One hundred invasive breast carcinomas were reviewed and fluorescence in situ hybridization analysis was performed in all cases. Immunohistochemical scores showed a perfect concordance with fluorescence in situ hybridization amplification ratios (p<0.0001). The results indicated a significant correlation between HER-2/neu and grade, but an inverse relationship between HER-2/neu and hormone receptors. In women aged ≤45 years, an inverse relationship between HER-2/neu and progesterone receptor was found and no association was noted between HER-2/neu and other factors. In women aged >45 years, the results indicated a significant correlation between HER-2/neu and grade, and there was an inverse relationship between HER-2/neu and hormone receptors.

Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013

“…However, our patients had slightly lower HR-positive rate than in Europe (74% vs 84%) and slightly higher HER2 receptor-positive rate than in United States (21% vs 15%) compared with Western patients. 18 , 28 , 36 – 39 The distribution of molecular subtypes and proportion of triple negative breast cancer were similar to that of other countries. 7 , 40 The major molecular subtype was Luminal B (51.5%), the proportion of which kept increasing during the 20 years.…”

Overexpression of HER-2/neu in Malignant Mammary Tumors: Translation of Clinicopathological Features from Dog to Human

“…In terms of the involved anatomic region as well as the histopathological results, this study was in line with other similar studies (Karyannopoulo et al, 2005;Andrade et al, 2010). Any change in the effect of the HER-2/neu gene in HBC is related to tumor grading since, by activating epidermal growth factor receptor 2, both tumor cell proliferation pathways and the cellular growth cycle are activated (Ramadan et al, 2011). The result of activating the cellular growth cycle is the emergence of several mitotic figures in tumor cells, and several anisocytoses and anisokaryoses are observed.…”

Immunohistochemiluminescence Detection: A Quantitative Tool in Breast Cancer HER-2 Status Evaluation

“…In the last decades it has been observed an increasing incidence of breast cancer with growing mortality rates [14]. Today immunohistochemistry (IHC) is the most used method to evaluate prognostic and therapeutic response including Her-2 status due to its relatively low cost [15].…”